Arti Bhan, MD
Endocrinology, Diabetes & Metabolism · Detroit, MINPI 1346318870
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (52.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Zimmer Biomet at 52.9% of the total. Reporting peaked in 2019 at $344 and has fallen 65.7% since, to $118 in 2023. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in MI, where the typical reported total is $1,470.
Across 6 payments — averaging $108.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$344
- Amgen$118
- Novo Nordisk$106
- Radius Health, Inc.$59
- Xeris Pharmaceuticals, Inc.$12
- Lilly USA, LLC$12
Across 349 payments — averaging $852.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$194K
- Novo Nordisk AS$100K
- Lexicon Pharmaceuticals, Inc.$4K
What the payments were for
- Travel & lodging$34453%
- Food & beverage$28243%
- Education$244%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 1 | $344 |
| Amgen | 1 | $118 |
| Novo Nordisk | 1 | $106 |
| Radius Health, Inc. | 1 | $59 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$650 in reported general payments places this provider in the 35th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $126,785 |
| JardianceEmpagliflozin | 74 | $116,788 |
| MounjaroTirzepatide | 75 | $114,370 |
| TrulicityDulaglutide | 54 | $111,630 |
| JanuviaSitagliptin Phosphate | 35 | $44,307 |
| Novolog FlexpenInsulin Aspart | 87 | $24,647 |
| RybelsusSemaglutide | 11 | $24,465 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 108 | $17,518 |
| FarxigaDapagliflozin Propanediol | 11 | $16,880 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $9,223 |
| NovologInsulin Aspart | 21 | $8,349 |
| Levothyroxine Sodium | 411 | $5,738 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 29 | $5,007 |
| SynthroidLevothyroxine Sodium | 47 | $4,687 |
| Humalog Kwikpen U-100Insulin Lispro | 15 | $4,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin N | $12 | $226,705143 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $106 | $159,600103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Detroit
- Henry BoneDetroit$120K
- Shobana AthimulamDetroit$14K
- Wael TahaDetroit$12K
- Berhane SeyoumDetroit$11K
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.